| Literature DB >> 15976815 |
Alasdair Breckenridge1, Kent Woods, June Raine.
Abstract
The withdrawal of the selective cyclooxygenase 2 inhibitor rofecoxib owing to cardiovascular side effects ignited debate about the need for major changes to current mechanisms for post-marketing surveillance (PMS) of drug safety. Here, we discuss the current mechanisms, whether they are being used appropriately, and consider the need for changes to regulatory systems.Entities:
Mesh：
Year: 2005 PMID： 15976815 DOI： 10.1038/nrd1778
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694